A DNA-binding Gd chelate for the detection of cell death by MRI

Elisabeth Garanger1, Scott A Hilderbrand, Joseph T Blois

  • 1Center for Molecular Imaging Research, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Chemical Communications (Cambridge, England)
|July 15, 2009
PubMed

Insights

GadoTO is a novel MRI contrast agent designed to detect cell death. It combines a gadolinium chelate with a fluorophore that binds to nucleic acids, enabling targeted imaging.

Area of Science:

  • Biomedical imaging
  • Molecular imaging
  • Cellular imaging

Background:

  • Accurate detection of cell death is crucial for diagnosing and monitoring various diseases.
  • Current methods for detecting cell death have limitations in sensitivity and specificity.
  • Novel contrast agents are needed to improve the visualization of cell death in vivo.

Purpose of the Study:

  • To introduce GadoTO, a novel magnetic resonance (MR) contrast agent.
  • To evaluate GadoTO's capability in detecting cell death.
  • To demonstrate the potential of GadoTO for molecular imaging applications.

Main Methods:

  • GadoTO was synthesized by conjugating a nucleic acid-binding fluorophore to a gadolinium chelate.
  • The binding properties of GadoTO to nucleic acids were characterized.
  • The efficacy of GadoTO as an MR contrast agent for detecting cell death was assessed in vitro and potentially in vivo models.

Main Results:

  • GadoTO demonstrated specific binding to nucleic acids.
  • GadoTO exhibited contrast enhancement in MR imaging.
  • The agent showed potential for detecting markers of cell death.

Conclusions:

  • GadoTO represents a promising new MR contrast agent for cell death detection.
  • Its nucleic acid-binding property allows for targeted imaging.
  • Further studies are warranted to explore its full clinical potential in various pathological conditions.